Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Losses ⢠Negative Cash Flow ALMS has strong liquidity and low debt, but severe losses, cash burn, and high valuation multiples make it a high-risk investment.
Price Behavior
Key Price Behavior Insights: ⢠Sharp breakdown ⢠Weak rebound ⢠Oversold momentum Support Level: $9.47 Resistance Level: $11.36; $21.81â$23.03 ALMS remains bearish over the last month; despite oversold conditions and a bounce from $9.47, downside risk persists unless it holds support and breaks above $11.36.
Sentiment & News
Key News Insights: ⢠Lupus Trial Failed ⢠Psoriasis Data Strong ⢠Q4 Filing Planned Alumis' lupus trial failure pressured shares, but strong psoriasis data and a planned Q4 filing keep its lead program central to the outlook.
AI Summary
ALMS is now a high-variance, psoriasis-led catalyst tradeânot a diversified autoimmune storyâwith upside contingent on maintaining its Q4 2026 psoriasis NDA timeline and proving the interferon-high lupus subgroup in a regulator-backed trial, while sustained cash burn raises dilution risk if execution slips.
Description
Alumis Inc. is a clinical-stage biopharmaceutical company developing allosteric TYK2 inhibitors to treat autoimmune conditions. Its lead program, ESK-001, is in clinical development for dermatologic, systemic and ocular autoimmune disorders, while A-005 is a CNS-penetrant candidate intended for neuroinflammatory and neurodegenerative indications. The company was incorporated in 2021, renamed from Esker Therapeutics in January 2022, and is based in South San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 29 | Feb 5 | ALMS | Alumis Inc. Common Stock | Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst. | Closed | -1.9% |
| Jan 7 | Jan 14 | ALMS | Alumis Inc. Common Stock | Selected due to recent Phase 3 clinical trial success on 2026-01-07 driving strong near-term momentum and technical breakout; event-driven upside expected from FDA submission and regulatory catalysts. | Closed | +35.8% |